atepeq/tico19 huggingface dataset:
Around 24 January 2020 in Australia, the University of Queensland announced that it is investigating the potential of a molecular clamp vaccine that would genetically modify viral proteins in order to stimulate an immune reaction.
ኣብ ኣዉስትራልያ ክዊንስላንድ ዩኒቨርስት አብ ከባቢ ጥሪ 24, 2020፡ ነቲ ብቕዓት ክታበት ናይ ሞለክዮል መቀርቀር ክምርምር ኣዉጁ፡ እዚ ንጀነቲካል ናይ ቪራል ፕሮቲን የተዓራሪ፡ ካብ ሕማም ነጻ ናይ ምዃን ግብረ መልሲ ምእንቲ ከነቓቕሕ።
Around 24 January 2020 in Canada, the International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan announced the commencement of work on a vaccine, aiming to start human testing in 2021.
ኣብ ከባቢ 24 ጥሪ 2020 ኣብ ካናዳ ማእከል ኣህጉራዊ ክታበት (VIDO-InterVac) ኣብ ዩኒቨርስቲ ሳስካችዋን ምጅማር ስራሕ ናብ ደቂ ሰባት ዝዓለመን ፈተነ ኣብ 2021 ከም ዝጅምር ይሕብር።
Vaccine development projects were announced at the Chinese Center for Disease Control and Prevention on 26 January 2020, and the University of Hong Kong on 28 January.
ትልሚ ምዕባለ ክታበት ኣብ ቻይና ማእከላይ መቆጻጸሪ ሕማም፡ምክልኻል ኣብ 26ጥሪ 2020፡ ኣብ ዩኒቨርሲቲ ናይ ሆንግኮንግ ኣብ ጥሪ 28 ተሓቢሩ።
Around 29 January 2020, Janssen Pharmaceutical Companies, led by Hanneke Schuitemaker, announced that it had begun work on developing a vaccine.
ኣብ ከባቢ 29 ጥሪ 2020፡ ጀንሰን ናይ ፋርማሲ ካምፓኒ፡ ብ ሃንኪ ሻትመከር ዝምራሕ፡ ኣብ ምምዕባል ክታበት ስራሕ ከም ዝጀመረ ብዕሊ ነጊሩ።
Janssen is co-developing an oral vaccine with its biotechnology partner, Vaxart.
ጀንሰን ሓደ ተሓባባሪ ናኡ ኣፋዊ መድሃኒት ኮይኑ ምስቲ ናይ ቢዮ-ተክኖሎጂ (biotechnology) ዓርኩ ድማ ይሻረኽ።
On 18 March 2020, Emergent BioSolutions announced a manufacturing partnership with Vaxart to develop the vaccine.
ብ መጋቢት 18, 2020, ሓዲሽ ባዮሶልሽን ንናይ ስናዓ ሽርክነት ምስ ቫዛርት(Vaxart) ንክታበት ከም ዝጀመረ ኣፍለጠ።
On 8 February 2020, the laboratory OncoGen in Romania published a paper on the design of a vaccine with similar technology to the one used for cancer neoantigen vaccination therapy.
ኣብ 8 ለካቲት 2020 ምርምር ኦንሶጀን(OncoGen) ኣብ ሮማኒያ ብዛዕባ ንድፈ ክታበት ብዝተማሳሰለ ምዕባለ ምስ ኣቀዲሙ ዝጥቀሙሉ ዝነበሩና ካንሰር ኔኦኣንቲጂን ክታበት ኣሕቲሙ ኢዩ።
On 25 March the head of the research institute announced that they had finalized the synthesis of the vaccine and were beginning the tests.
ኣብ መጋቢት 25፡ ሓላፊ ናቲ ናይ መጽናዕቲ ጉጅለ፡ እቲ ምምስራሕ ናይ ክታበት ከምዝወድእዎን ኣብ ፈተነ ከም ዝርከቡን ኣፍሊጡ።
On 27 February 2020, a Generex subsidiary company, NuGenerex Immuno-Oncology, announced they were beginning a vaccine project to create an Ii-Key peptide vaccine against COVID-19.
ኣብ ለካቲት 27, 2020 ጀነረክስ ተወሳኺ ኩባንያ ጁነረክስ ኢሙኒ-ኦንኮሎጂይ ክታበት ከምዝጀመሩ ኣዋዓዊዑ።እቲ ናይ ክታበት ትልሚ ሊ-ከይ ፐፕሲ ናይ ክታበት ኣንጻር ኮቪድ19 እዩ።
They wanted to produce a vaccine candidate that could be tested in humans "within 90 days."
ኣብ ውሽጢ 90 መዓልታት ኣብ ሰባት ዝፍተን ዓይነት ክታበት ከፍርዩ ይብገሱ ኣለዉ።
On 5 March 2020, Washington University in St. Louis announced its projects to develop a vaccine.
ኣብ መጋቢት 5, 2020 ኣብ ቅዱስ ሎኢስ ዋሽንግተን ዩኒቨርስት ናይ ክታበት ክትመታቶም(ፕሮጀክት) ከምዘማዕብሉ ኣፍሊጦም።
On 5 March 2020, the United States Army Medical Research and Materiel Command at Fort Detrick and the Walter Reed Army Institute of Research in Silver Spring, both in western Maryland, announced they were working on a vaccine.
ኣብ 5 መጋቢት ናይ 2020፡ ናይ ሕቡራት መንግስታት ኣሜሪካ ወተሃደራዊ ናይ መጽናዕቲ ጉጅለ ምስ ናይ ንብረት ኣማሓዳሪ ጉጅለ ኣብ ፎርት ደትሪክ ከምኡውን ዋልተር ረአድ ወተሃደራዊ ናይ መጽናዕቲ ጉጅለ ኣብ ሲልቨር ስፕሪንግ፡ ኩሎም ክታበት ከማዕብሉ ብሓንሳብ ይሰርሑ ከም ዘለዉ ነጊሮም።
Around 10 March 2020, Emergent Biosolutions announced that it had teamed with Novavax Inc.
ኣብ ከባቢ 10 መጋቢት 2020፡ ኢመርጀንት ባይ ሶሊሽኝ ፡ምስ ናቫቫክዝ Inc ከም ዝተሓወሰ ነጊሩ
in the development and manufacture of a vaccine.
ኣብ ምዕባለን ምህዞ ናይ ክታበት።
The partners further announced plans for preclinical testing and a Phase I clinical trial by July 2020.
እቶም ተሻረኽቲ ክንዮ እቲ መደባት ን ቅድመ ክሊንካዊ ፈተናንን ኣብ ገጽ1 ክሊኒካዊ መርመራ ብ ነሓሰ 2020 ሓቢሮም።
On 12 March 2020, India's Health Ministry announced they are working with 11 isolates, and that even on a fast track it would take at least around one-and-a-half to two years to develop a vaccine.
ኣብ 12 መጋቢት 2020 ሚኒስትሪ ጥዕና ህንዲ ምስ 11 ዝተነጸሉ ሰባት ከም ዝሰርሑ ሓቢሩ።እቲ መስርሕ ክታበት ቀልጢፉ ተባሂሉ ድማ ዓመትን ፈረቃን ወይ ክልተ ዓመት ከም ዝወስድ ሓቢሮም።
On 12 March 2020, Medicago, a biotechnology company in Quebec City, Quebec, reported development of a coronavirus-like particle under partial funding from the Canadian Institutes for Health Research.
ኣብ 12 መጋቢት 2020 መድካጎ ስነ ሂወት ምርምር ቴክኖሎጂ ካምፓኒ ኣብ ኩበክ ከተማ ቦታ ኩበክ ብካናዳ ምርምር ጥዕና ኢኒስቲቱት ብዝተዋህበ ገንዛባዊ ደገፍ’ኮሮና ቫይረስ-መሰል ነገር ከማዕብሉ ከምዝጀመሩንን ውጺት ውን ከም ዝረኸበን ተፈሊጡን ተሓቢሩን ኣሎ
The vaccine candidate is in laboratory research, with human testing planned for July or August 2020.
ናይ ክታበት ሕጹያት ኣብ ላባራቶሪ ምርምር እዮም ዘለዉ። እቲ መደብ ንሓምለ ወይ ጥቕምቲ 2020 ኣብ ደቂሰባት ፈተነ ንምጅማር እዩ።
Earlier that week, The Guardian reported that the US President Donald Trump had offered CureVac "'large sums of money' for exclusive access to a Covid-19 vaccine", against which the German government protested.
ኣብቲ መጀመርያ ሰሙን ናይ ሕቡራት መንግስትታት ኣሜሪካፕረዚደንት ዶናልድ ትራምፕ ክዩርቫክ”ኣዝዩ ብዙሕ ገንዘብ” ንምእታው ክታበት ኮቪድ 19 ንምረኻብ ከምዝወፈየ ጋርዲያን ኣመሓላሊፉ፡ መንግስቲ ጀርመን ከኣ ተቃዊሙዎ።
On 17 March 2020, American pharmaceutical company Pfizer announced a partnership with German company BioNTech to jointly develop a mRNA-based vaccine.
ኣብ መጋቢት 17, 2020፡ ኣመሪካዊ ናይ ፋርማሲ ትካል ፕፊዘር ምስ ናይ ጀርመን ትካል ባዮተክ ዝምድና ከም ዝገበረ ነጊሩ፡ ዕላማ ኡ ድማ ነቲ ኣብ mRNA-based ዝምርኮስ ክታበት ንምምዕባል ኢዩ።
mRNA-based vaccine candidate BNT162, currently in pre-clinical testing with clinical trials expected to begin in April 2020.
ኣብ mRNA ዝተመርኮሰ ክታበት ናይ BNT162 ግዝያዊ ሕጹይ ቅድመ ክሊኒካዊ መርመራ ምስ ክሊኒካዊ መርመራ ኣብ ሚያዝያ 2020 ክጅመር ትጽቢት ይግበረሉ።
In Italy on 17 March 2020, Takis Biotech, an Italian biotech company announced they will have pre-clinical testing results in April 2020 and their final vaccine candidate could begin human testing by fall.
ኣብ 17, መጋቢት 2020፡ ታኪስ ባዮ-ተክ ዝተባህለ ናይ ጣልያን ናይ መድሃኒት ዝምስርሕ ትካል፡ ቅድመ-ክሊኒካዊ ውጽ ኢት ኣብ መጋቢት 2020፡ እቲ ናይ መወዳእታ ናይ ክታበት መወዳደሪ ውጽ ኢት ድማ ኣብ ከባኢ ምጅማር መስከረም ኣብ ሰባት ክፍትን ክጅምር ከም ዝኾነ ገሊጹ።
In France on 19 March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced a US$4.9 million investment in a COVID-19 vaccine research consortium involving the Institut Pasteur, Themis Bioscience (Vienna, Austria), and the University of Pittsburgh, bringing CEPI's total investment in COVID-19 vaccine development to US$29 million.
ኣብ ፈረንሳ፡ ኣብ 19 መጋቢት ናይ 2020፡ ውህደት ን ምልባዕ ናይ ምድላው ምሕዳስ (CEPI)፡ $4.9 ሚልዮን ዶላር ፡ ን ምምዕባል ናይ ኮቪድ-19 ክታበት ዝውዕል ኣብ ምርምር ኣዳልዩ፡ እዚ ድማ ፓስተር ኢንስቲቱት፡ ተሚስ ባዮ-ሳይንስ (ቬና ኣውስትራልያ)፡ ፒተስበርግ ዩኒቨርሲቲ ዘጠቃለለ ኮይኑ፡ ናቲ ናይ CEPI ናይ ኮቪድ-19 ናይ ክታበት ምምዕባል ድምር ወፍሪ ናብ $29 ሚልዮን ዶላር ኣዕብይዎ
CEPI's other investment partners for COVID-19 vaccine development are Moderna, Curevac, Inovio, Novavax, the University of Hong Kong, the University of Oxford, and the University of Queensland.
ናይ CEPI ካልእ ናይ ወፍሪ ኣዕሩኽ ን ኮቪድ-19 ክታበት ንምምዕባል እዞም ዝስዕቡ ኢዮም፡ ሞዴራ፡ ኩረቫክ፡ ኢኖቪኦ፡ ናቫቫክስ፡ ዩኒቨርሲቲ ናይ ሆን ኮንግ፡ ዩኒቨርሲቲ ናይ ኦክስፎርድ፡ ከምኡውን ዩኒቨርሲቲ ናይ ክዊንስላንድ ኢዮም
On 20 March 2020, Russian health officials announced that scientists have begun animal testing of six different vaccine candidates.
ኣብ 20 መጋቢት 2020 ተመራመርቲ ጥዕና ሩስያ ወግዓዊ ከምዝሓቦሮ ሹድሽተ ዓይነት ክታበት እንስሳ ፈተነ ጀሚሮም።
Imperial College London researchers announced on 20 March 2020 that they are developing a self-amplifying RNA vaccine for COVID-19.
ኣብ ኢምፐርያል ኮለጅ ናይ ሎንዶን ናይ መጽናዕቲ ጉጅለ፡ ኣብ 20 መጋቢት 2020፡ ነብሰ-ብርትዐ ዝውስኽ ሓደ ናይ RNA ክታበት ናይ ኮቪድ-19 የዳልዉ ኣለዉ።
The vaccine candidate was developed within 14 days of receiving the sequence from China.
ናይ ክታበት ሑጹያት ኣብ ውሽጢ 14 መዓልታት ካብ ቻይና እቲ መስርሕ ምስ ተቀበሉ ምዕባለታት ኣርእዮም።
In late March, the Canadian government announced C$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian companies and universities, such as the Medicago and University of Saskatchewan initiatives.
ኣብ መወዳእታ መጋቢት መንግስቲ ካናዳ 275 ካናድያን ዶላር ን96 ምርምር ፕሮጀክትታት ሕምናዊ ኣንጻር ኮቪድ-19 ከምኡ’ውን ንቡዙሓት ናይ ክታበት ሑጺያት ትካላትን ዩኒቨርስታትን ከም በዓል መዲካጎን(Medicago) ዩኒቨርስቲ ናይ ሳስካቹዋን ከም ዝመወለ ሓቢሩ።
Around the same time, the Canadian government announced C$192 million specifically for developing a COVID-19 vaccine, with plans to establish a national "vaccine bank" of several new vaccines that could be used if another coronavirus outbreak occurs.
ኣብ ሓደ ግዜ መንግስቲ ካናዳ ናይ c$192 ሚልዮን ዝኸውን ክታበት ኮቪድ-19 ንምፍላይ ኣዊጃ።እቲ መደብ ከኣ ሃገራዊ "ክታበት ባንኪ "ንምምስራት እዩ።ከም ተወሳኺ ካልእ ክታበታት ከኣ ንመጻኢ ዝኾና ሓዲሽ ኮቪድ ንኸየጋጥም።
On 2 April 2020, researchers at the University of Pittsburgh School of Medicine reported on testing of PittCoVacc, a possible COVID-19 vaccine in mice, stating that "MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses [in the mice] that were evident beginning 2 weeks after immunization."
ኣብ ሚያዝያ 2, 2020 ኣብ ዩኒቨርሲቲ ፒትስበርግ ናይ ቤት ትምህርቲ መድሃኒት ዝለዉ ኣጽናዕቲ ናይ ፒትኮቫክ (PittCoVacc) ፈተነ ተክእሎታት ክታበት ኮቪድ-19 ኣብ ኣናጹ ፈቲኖሞ። ከምዚ ኢሉ “MNA SARS-CoV-2 S1 ኣብጺሑክታበት ንኡስ ኣሃዱ ብቑዕ ኣንቲጀን ብፍሉይ ግብረ መልሲ ጸረ-ኣካላት ኣብ ኣናጹ ኣፍሊጡ።ክልተ ሰሙን ድሕሪ ዘይምጽያን መጅመርያ መርትዖ እዩ ነይሩ።
In Canada on 16 April 2020, the University of Waterloo School of Pharmacy announced design of a DNA-based vaccine candidate as a possible nasal spray.
ኣብ 16 መጋቢት 2020, ኣብ ካናዳ፡ ዩኒቨርሲቲ ናይ ዋተርሎ ናይ ፋርማሲ ቤትትምህርቲ፡ DNA-ዝተመርኮሰ ንድፊ ናይ ክታበት ንድፊ፡ ተወዳደርቲ ኣቕሪባ።
Using bacteriophages, the DNA will be designed to replicate inside human bacteria to produce harmless virus-like particles, which may stimulate the immune system to produce antibodies against the SARS-CoV-2 virus.
ባክተርዮፌጅ (bacteriophages) ብምጥቃም፡ እቲ DNA ኣብ ውሽጢ ናይ ወዲ ሰብ ባክተርያ ኮይኑ ሓደ ዘይጋዳእ ቫይረስ ዝዓይነቱ ነገር ከፍሪ ይኽእል ኢዩ፡ እዚ ድማ ነቲ ስርዓተ ምክልኻል ብምልዓል ጸረ-ነፍሳት ኣንጻር SARS-CoV-2 ቫይረስ፡ ዝዓለመ ከፍሪ ድማ ተኽእሎታት ኣሎ
In March 2020, the US government, industry, and three universities pooled resources to access supercomputers from IBM, combined with cloud computing resources from Hewlett Packard Enterprise, Amazon, Microsoft, and Google.
ኣብ መጋቢት 2020፡ መንግስቲ ኣሜሪካ፡ ትካል፡ ከምኡ’ውን 3 ዩኒቨርሲታት ካብ IBM ነተን ኣዝየን ቅልጡፋት ኮምፒተራት ክጥቀሙ ፍቃድ ረኺቦም፡ እዚ ድማ ብምትሕብባር ምስ ናይ ክላውድ ኮምፒቲንግ ማእከል ካብ ሃዋለት ፓካርድ ኢንተርፕሪሰ፡ ኣማዞን፡ ማይክሮሶፍት፡ ከምኡ’ውን ጎግለ፡ ዝተገብረ ኢዩ
Some vaccines have heterologous effects, also called non-specific effects.
ገለገለ ክታበታት ሕውስዋስ ጽልዋ ወይንጹር ዘይኮነ ጽልዋ ዝብሃል ኣለዎም።
That means they can have benefits beyond the disease they prevent.
እዚ ድማ ካብቲ ዝከላኸሎ ሕማም ሓሊፉ፡ ክልቲኦም ጥቅሚታት ይለዋወጡ ኢዮ።
A further randomized trial in Australia is seeking to enrol 4,170 healthcare workers.
እቲ ካልእ ብሃውሪ ዝግበር ፈተነ ኣብ ኣውስትራልያ ድማ፡ 4170 ሰራሕተኛታት ናይ ጥዕና ይደሊ
It is possible vaccines in development will not be safe or effective.
እቶም ክታበታት ኣብ ምዕባለታት ለውጢ ዘይከምጽኡ ተኽእሎታት ከም ዘለዎም ድማ ተሓቢሩ።
Early research to assess vaccine efficacy using COVID-19-specific animal models, such as ACE2-transgenic mice, other laboratory animals, and non-human primates, indicate a need for biosafety-level 3 containment measures for handling live viruses, and international coordination to ensure standardized safety procedures.
ኣቀዲሙ ዝነበረ ምርምር ናይ ክታበታት ርክበታት ቅማረ ብ ናይ ኮቪድ-19 ፍሉያት ሞደል ክኾኑና ዝኽእሉ እንስታት፡ ተሞርኪሶም ከም ACE2 ናብ ኣናጹ ብምትሕልላፍ፡ ካልኦት ምርምር እንስታትን ከምኡዉን ሰባት ዘይኮኑ መጥበዉትን፡ ከም ዝሕብርዎ ስነሂወታዊ-ውሕስነት ደረጃ 3 ናይ ምቁጽጻር መስርሕ ነቶም ብሂወት ዘለዉ ቫይረስን ከምኡውን ዓለማዊ ምትሕብባር ደረጃ ዝሓለወ ናይ ውሕስነት ምድላው ኣንፈት ከም ዝህብ ኢዩ።
Vaccines against SARS and MERS have been tested in non-human animal models.
ክታበት ኣንጻር ሳርስ መርስን ኣብ ሰባት ዘይኮኒ እንስሳታት ተፈቲኑ።
As of 2020, there is no cure or protective vaccine for SARS that has been shown to be both safe and effective in humans.
ክሳብ 2020፡ ዝኾነ ን ደቂ-ሰባት ውሑስን ውጽኢታዊን ዝኾነ ፈውሲ ወይ መከላኸሊ ክታበት ናይ SARS የለን
According to research papers published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and public health agencies around the world.There is also no proven vaccine against MERS.
ብመሰረት እቲ ኣብ 2005 ን 2006 ዝተገብረ ን ዝተሓትመ መጽናዕቲ፡ እቲ ምፍላጥን ምምዕባልን ናይ ኖቨል ክታበትን መድሃኒታትን ን ምፍዋስ SARS፡ ን መንግስታት ን ናይ ህዝቢ ጥዕና ማእከላትን ኣብ ዓለም ቀዳምነተን ኢዩ ኔሩ ከም ተወሳኺ ን MERS ተባሂሉ ዝተሰርሐ ዝተረጋገጸ መድሃኒት የሎን
When MERS became prevalent, it was believed that existing SARS research may provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection.
MERS ልሙድ ምስ ኮነ ናይ SARS መጽናዕቲ ምክያዱ ንምዕባለ ክታበትን ኣንጻር መልከፍቲ MERS-CoV ኣዝዩ ሓጋዚ ብልሒ ክኸውን ይኽእል እዩ።
As of March 2020, there was one (DNA based) MERS vaccine which completed phase I clinical trials in humans, and three others in progress, all of which are viral-vectored vaccines, two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac), and one MVA-vectored (MVA-MERS-S).
ካብ መጋቢት 2020 ጀሚሩ ሓደ (ኣብ ዲ ኤን ኤ ዝተሞርከሰ) መርስ( MERS) ክታበት ቀዳማይ ገጽ ናይ ክሊኒካዊ ፈተነ ዝዛዘመ ኣብ ወዲ ሰብ ንካልኦት ሰለስተ ቫይራል-ቬክቶርድ ክታበት(viral-vectored vaccines) ዝኾኑ (ክልተ ኣደኖቪራል ቬክቶርድ(adenoviral-vectored)) (ChAdOx1-MERS, BVRS-GamVac)፣ሓደ ድማ ኤም ቪ ኤ(MVA) ቬክቶርድ(MVA-MERS-S) ኣብ መስርሕ ነበሩ
Social media posts have promoted a conspiracy theory claiming the virus behind COVID-19 was known and that a vaccine was already available.
ማሕበራዊ ማዕከናት ንውዲት ክልሰ-ሓሳብ እዚ ቫይረስ ብድሕሪት ኮቪድ-19 ዘሎ ከም ዝተፈልጠ ንክታበት’ውን ከም ዘሎ ኣፍሊጠን።
The patents cited by various social media posts reference existing patents for genetic sequences and vaccines for other strains of coronavirus such as the SARS coronavirus.
እቶም ምስክራት ብብዙሕ ዝርጉሕ ማሕበራዊ መራከቢታት ዝጠቀሱ ዝነበሩ ምስክራት ናይ ተኸታታሊ ዉርሻዊ ከምኡ’ዉን መድሃኒታት ናይ ዝተፈላለዩ ዝተዳከሙ ኮሮና ቫይረስ ከም በዓል ሳርስ ኮሮና ቫይረስ።
b'Coronaviruses are a group of related viruses that cause diseases in mammals and birds.
B`ኮሮና-ቫይረስ ሓደ እክብካብ ናይ ዝመሳሰሉ ዓይነታት ቫይረሳት ኮይኑ ኣብ መጥበውቲ ጥራይ ሕማም ከስዕብ ይኽእል።
In humans, coronaviruses cause respiratory tract infections that can range from mild to lethal.
ኣብ ደቂ ሰባት፡ ኮሮና ቫይረስ ካብ ፈኪስ ክሳብ ቀታሊ ዝኾነ ደረጃ ናይ ምስትንፋስ ረኽሲ ከስዕብ ተኽእሎታት ኣለዎ።
Mild illnesses include some cases of the common cold (which has other possible causes, predominantly rhinoviruses), while more lethal varieties can cause SARS, MERS, and COVID-19.
ፎኪስ ሕማም ከም ሰዓል የጠቃልል( ሰዓል ካልእ ሕማም ራይኖ ቫይረስ ከስዕብ ይክእል) ካልኦት ዝተፈላለዩ ሓደገኛታት ሕማማት ከም በዓል ሳርስ፡ መርስን (SARS፡ MERS) ኮቪድ-19 ከስዕቡ ይኽእሉ።
Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea.
ምልክታት ሕማም ኣብ ካልኦት ህይወታዉያን ይፈላለ፡ ኣብ ጨቃዊት ላዕለዋይ ሕማም ምስትንፋስ የምጽእ።
There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections.
ናይ ደቂ ሰባት ክታበት ወይ ድማ መድሃኒት ብሕጂ እዮም ክስርሑ።
Coronaviruses constitute the subfamily Orthocoronavirinae, in the family Coronaviridae, order Nidovirales, and realm Riboviria.
ኮረናቫይረስ ንንኡስ ስድራ ኦርቶኮሮናቪሪና ፡ካብ ስድራ ኮሮናቢሪዳ፡መስርዕ ኒዶቪራልስን ኣየራት ሪቦቪርያ።
They are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry.
እዚኦም ብኣወንታ-ስሚዒት ንጽል ግዱዕ RNA ጂኖምን ንዩክሎካፕሲድ ናይ ዝንቅነት ዝተሸፈኑ ቫይረሳት እዮም።
The genome size of coronaviruses ranges from approximately 26 to 32 kilobases, one of the largest among RNA viruses.
ዝርግሐ ናይ ኮሮናቫይረሳት ዓቐን ጂኖም ብገምጋም ካብ 26 ናብ 32 ኪሎበይዝስ እዩ።እዚ ሓደ ካብቶም ዝዓበየ ኣብ ማእከል RNA ቫይረሳት እዩ።
They have characteristic club-shaped spikes that project from their surface, which in electron micrographs create an image reminiscent of the solar corona from which their name derives.
ካብ ኣካላቶም ዝወጽእ በሊሕ ክለብ-ዝቅርጹ ጫፍ ኣለዎም፡ እዚ ድማ ካብቲ አለክትሮን ማይክሮግራፍ ካብ ናይ ጸሓይ ዝፈጥሮ ዝረኣይ ስእሊ ናይ ኮሮና ዝመጸ ሽም ኢዩ።
Coronaviruses were first discovered in the 1930s when an acute respiratory infection of domesticated chickens was shown to be caused by infectious bronchitis virus (IBV).
ኮሮና ቫይረስ ኣብ 1930 ኣብ ደርሆ ንጡፍ ምስትንፋስ ለበዳ ብነድሪ ሳንቡእ ቫይረስ (IBV) ከም ዝተረኽበ ይፍለጥ።
In the 1940s, two more animal coronaviruses, mouse hepatitis virus (MHV) and transmissible gastroenteritis virus (TGEV), were isolated.Human coronaviruses were discovered in the 1960s.
ኣብ 1940 ክልተ ናይ እንስሳ ኮሮና ቫይረስ (CORONA VIRUS)፣ ናይ ኣንጭዋ ሀፐታቲስ ቫይረስ (HEPATITIS VIRUS (MHV))ንተመሓላላፊ GASTROENTERITIS VIRUS (TGEV) ተገሊሎም እዮም። ናይ ደቂ ሰባት ኮሮና ቫይረስ ኣብ 1960 ተረኺቡ።
The earliest ones studied were from human patients with the common cold, which were later named human coronavirus 229E and human coronavirus OC43.
ኣቐዲሙ ከም ዝተጸንዐ፡ካብ ሕሙማት ሰባት ሓደ ሳዓል ዝሓመመ ድሒሩ ኮሮናቫይረስ 229E ን ናይ ሰባት ኮሮናቫይረስ OC43 ተሰምዩ።
They were first imaged by Scottish virologist June Almeida at St. Thomas Hospital in London.
ኣብ መጀመርታ ብ ናይ ስኮትላንዳዊ ቫይሮሎጂስት ጁነ ኣለማንዳ ኣብ ቅዱስ. ቶማስ ሆስፒታል ኣብ ሎንዶን ኢዩ ተቀሪጹ/ተሳኢሉ።
Other human coronaviruses have since been identified, including SARS-CoV in 2003, HCoV NL63 in 2004, HKU1 in 2005, MERS-CoV in 2012, and SARS-CoV-2 in 2019.
ክሳብ ሕጂ ተፈሊጦም ካብ ዘለዉ ካልኦት ዓይነታት ናይ ወዲ-ሰብ ኮሮና-ቫይረስ እዞም ዝስዕቡ ኢዮም፡ SARS-CoV ኣብ 2003, HCoV NL63 ኣብ 2004, HKU1 ኣብ 2005, MERS-CoV ኣብ 2012, and SARS-CoV-2 ኣብ 2019
Most of these have involved serious respiratory tract infections.
ዝበዝሑ ካብዚኦም ጸገም ናይ ምስትንፋስ ዘጋተሞም እዮም።
The name was first used in 1968 by an informal group of virologists in the journal Nature to designate the new family of viruses.
እዚ ስም እዚ ን መጀመርያ ግዜ ኣብ 1968 ብ ዘይወግዓዊያን ጉጅለ ናይ ቫይሮሎጂስት ኣብ ፡ጆርናል ኔቸር፡ ተጠቂሞምሉ፡ እዚ ድማ ነቶም ሓደሽቲ ናይ ቫይረስ ስድራቤት ንምግላይ ተባሂሉ ኢዩ።
The name refers to the characteristic appearance of virions (the infective form of the virus) by electron microscopy, which have a fringe of large, bulbous surface projections creating an image reminiscent of a crown or of a solar corona.
እቲ ሽም ንባህርያትን መልክዕን ናይቲ ቫይረስ ብኤሌትሮን ማይክሮስኮብ ምስ ተራእየ፡ ዘፈር ዘፈሩ ክብብ ዝበለ ዓቢ ኮይኑ ኣብ ጫፉ ከም ናይ ኣኽሊል ስእሊ ዘለዎ እዩ።
This morphology is created by the viral spike peplomers, which are proteins on the surface of the virus.
እዚ ስነ-መዋቅር (morphology) በቲ ቫይረሳዊ ፖፕሎመር (peplomer) ዝተፈጥረ ኮይኑ እቶም ፕሮቲንስ ድማ ኣብ ላዕለዋይ ክፋል ኣለዉ
Coronaviruses are large pleomorphic spherical particles with bulbous surface projections.
ኮሮናቫይረሳት ዓበይቲ ፕሊሞርፊክ ክባዊ ንጥረታት ምስ ከቢብ ጽፍሒ ዉጡን እዩ።
The envelope of the virus in electron micrographs appears as a distinct pair of electron dense shells.The viral envelope consists of a lipid bilayer where the membrane (M), envelope (E) and spike (S) structural proteins are anchored.
መሸፈኒ ናይቲ ቫይረስ ኣብ ኤለክትሮን ማይክሮግራፍስ ከም ፍሉይ ጽምዲ ጽዑቅ ናይ ኤለክትሮን ድርዒ ኮይኑ ይርአእቲ ናይ ቫይረስ መሸፈኒ ሊፒድ ባይላየር መምብሬን(M)፡ መሸፈኒ(E)፡ ከምኡ’ዉን እስፓይክ(S) ቅርጻዊ ፕሮቲን መልህቅ የጥቃልል
The lipid bilayer envelope, membrane proteins, and nucleocapsid protect the virus when it is outside the host cell.
ሸፈነ ሊፒድ ቢለየር፡መምብረይን ፕሮቲናት፡ንዩክሎካፕሲድ እቲ ቫይረስ ካብ መዕቆቢኡ ወጻኢ ምስ ኮነ ይከላኸለሉ።
Coronaviruses contain a positive-sense, single-stranded RNA genome.
ኮሮና ቫይረስ ሓደ ኣወንታዊ-መልክዕ ፡ ንጽል-ፈትሊ ናይ RNA ጂኖም፡ ኣለዎ።
The genome size for coronaviruses ranges from 26.4 to 31.7 kilobases.
ናይ ኮሮናቫይረሳት ዓቐን ጂኖም ካብ 26.4 ክሳብ 31.7 ኪሎበይዝ ይምጠን።
The genome size is one of the largest among RNA viruses.
ጀኖም(genome) ብዓቐኑ ሓደ ካብቶም ዝዓበዩ ኣር ኤን ኤ ቫይረስ እዩ።
The open reading frames 1a and 1b, which occupy the first two-thirds of the genome, encode the replicase/transcriptase polyprotein.
እቲ ኣቃዉማ ክፉት ንባብ 1a ን 1b ን፡ እቲ መጀመርያ 2/3 ናይ ጂኖም የጠቃልል። እዚ ን ረፕሊካዝ/ትራንስክሪፕታስ ፖልይፕሮትን (replicase/transcriptase polyprotein) ይሓብእ።
The replicase/transcriptase polyprotein self cleaves to form nonstructural proteins.The later reading frames encode the four major structural proteins: spike, envelope, membrane, and nucleocapsid.
እዚ ረፕሊኬዝ/ትራንስክሪፕታስ ፖልይፕሮቲን (replicase/transcriptase polyprotein) ንዘይቅርጻዊ ፕሮቲናት ከቕዉም ገዛእ ርእሱ ይመቅል።እቲ ናይ መወዳእታ ንባብ ሰሌዳ ነዞም ቀንዲ ኣርባዕተ ቅርጻውያን ፕሮቲናት፡ ብልሒ፡ሰታሪት፡ መምብሬን ንዩክሎካፕሲድ (nucleocapsid) ይሽፍን።
Interspersed between these reading frames are the reading frames for the accessory proteins.
ሓሓሊፉ ዝኣተወ ኣብ መንጎ እዞም መንበቢ እቅርጽታት ተወሳኺ ፕሮቲናት መንበቢ ቅርጺ እዮም።
The number of accessory proteins and their function is unique depending on the specific coronavirus.
ብዝሒ ሓገዛት ፕሮቲናት ጥቅሞምን ኣብቲ ዓይነት ኮሮና ቫይረስ ይፈላለ።
Infection begins when the viral spike (S) glycoprotein attaches to its complementary host cell receptor.
እቲ ምልጋብ በቲ (S) ግላይኮፕሮቲን (glycoprotein) ዝተባህለ እሾኽ ወይ ወጋኢ ኣብቲ ኣኣንጋዲ ናይ ዋህዮ ተቀባሊ ምስተጣበቀ ይጂምር።
After attachment, a protease of the host cell cleaves and activates the receptor-attached spike protein.
ድሕሪ ምጥባቕ ፕሮቴዝ ናይ ኣአንጋዲ ዋህዮ ተፈንጪሉ ንተጣቢቑ ዘሎ እስፓይክ(spike) ፕሮቲን ተቐባሊ የንቀሳቕሶ።
Depending on the host cell protease available, cleavage and activation allows the virus to enter the host cell by endocytosis or direct fusion of the viral envelop with the host membrane.On entry into the host cell, the virus particle is uncoated, and its genome enters the cell cytoplasm.
ኣብ ናይ ፕሮቲን ዋህዮ ዘሎ ተጻባኢ እንተ ተሞርኪስና፡ እቲ ጋግ ከምኡ’ውን ምንቅስቃስ ነቲ ቫይረስ ናብቲ ተጻባኢ ዋሃዮ ብ ኢንዶሳይቶሲስ ወይ ከኣ ብቕጥታ ምጽንባር ናይቲ ጉልባብ ቫይራል ምስ ናይ ተጻባኢ መምብራና ንኽኣቱ ይሕግዝ። ኣብ ምእታው ናይቲ ተጻባኢ ዋሃዮ፡ ንኡስ ክፍሊ ናይቲ ቫይረስ ሹፉን ኣይኮነን፡ ከምኡ’ውን ናቱ ጂኖም ናብቲ ሳይቶፕላዝም ዋሃዮ ይኣቱ።
The host ribosome translates the initial overlapping open reading frame of the virus genome and forms a long polyprotein.
እቲ ኣኣንጋዲ ራይቦሶምነቲ ጀማሪ ተሓንጋሪ ክፉት ዝንበብ ፍሬም ናይ ቫይረስ ጀኖም የስቶርግሞ፡ ከምኡውን ሓደ ነዊሕ ፖሊፕሮቲን ይሰርሕ።
The polyprotein has its own proteases which cleave the polyprotein into multiple nonstructural proteins.
ፖልይፕሮቲን (polyprotein) ናይ ገዛእ ርእሱ ፕሮቲን ኣለዎ። እዚ ንፖልይፕሮቲን ኣብ ብዙሕ ዘይቅርጻዊ ፕሮቲንስ ይመቅል።
A number of the nonstructural proteins coalesce to form a multi-protein replicase-transcriptase complex (RTC).
እቲ ቁጽሪ ናይ ቅርጺ ኣልቦ ፕሮቲናት ብምትሕውዋስ ነቲ ማልቲ-ፕሮቲን ረፕሊከይስ-ትራንስክሪፕተይስ ፡ ሕውስዋስ (RTC) ፈጢሩ
The main replicase-transcriptase protein is the RNA-dependent RNA polymerase (RdRp).
እቲ ቀንዲ ረፕሊኬዝ-ትራንስክርፕቴዝ ፕሮቲን(replicase-transcriptase protein) ኣር ኤን ኤ ተሞርካሲ ኣብ ኣር ኤን ኤ ፖሊመራዝ( RNA-dependent RNA polymerase (RdRp))እዩ።
It is directly involved in the replication and transcription of RNA from an RNA strand.
ምብዛሕን ምቕዳሕን ኣር ኤን ኤይ(RNA) ካብ ኣር ኤን ኤይ ፈትሊ(RNA strand) ቀጥታዊ ርክብ ኣለዎ።
The other nonstructural proteins in the complex assist in the replication and transcription process.
እቶም ካልኦት ቅርጺ-ኣልቦ ፕሮቲናት ናይ ኮምፕለክስ ፡ ኣብቲ ሕውስዋስ ፡ ን ምብዛሕን ምቕዳሕን መስርሕ ይሕግዙ።
The exoribonuclease nonstructural protein, for instance, provides extra fidelity to replication by providing a proofreading function which the RNA-dependent RNA polymerase lacks.One of the main functions of the complex is to replicate the viral genome.
እዚ ኤግዞሪቦኒክለስ ቅርጺ-ኣልቦ ፕሮቲን፡ ከም ኣብነት፡ ን ምብዛሕ ተወሳኺ ምቹእነት ይፈጥር ፡ እዚ ድማ ነቲ RNA-ተወካሊ RNA ፖሊመርስል ፡ ስደልዮ ምክንዋን የመቻቻኣሉ። ሓደ ካብቶም ቀንዲ ስረሓት ናይቲ ቾምፕለጽ ነቲ ቫይረሳዊ ጂኖም ምብዛሕ ኢዩ።
RdRp directly mediates the synthesis of negative-sense genomic RNA from the positive-sense genomic RNA.
ኣር ዲ ኣር ፒ (RdRp) ኣሸምጊሊ የጸምሪ ኣሊታዊ ስምዒት ጀነሚክ ኣር ኤን (RNA) ኣየ ካብ ኣወንታዊ ስምዒት ጀኖሚክ ኣር ኤን ኣይ (RNA)።
This is followed by the replication of positive-sense genomic RNA from the negative-sense genomic RNA.
እዚ ምርባሕ ናይ ኣወንታዊ-ስምዒት ጀኖሚክ RNA ካብ ኣሉታ-ስምዒት ጀኖሚክ RNA ስዒቡ።
The other important function of the complex is to transcribe the viral genome.
እቲ ካልእ ጥቕሚ ድማ ንነጥበ ጽሑፍ ጸረ ጀኖም (genome)።
RdRp directly mediates the synthesis of negative-sense subgenomic RNA molecules from the positive-sense genomic RNA.
RdRp ብቐጥታ ነቲ ሲንተቲክ ናይ ኣሉታዊ-ህልዋት ሳብጀኖሚች RNA ሞሎኪል ካብ ኣሉታዊ-ህልዋት ሳብጀኖሚች RNA ብምጥቃም የተዓርቅ።
This is followed by the transcription of these negative-sense subgenomic RNA molecules to their corresponding positive-sense mRNAs.
እዚ ድማ ብ ምቕዳሕ ናይ እዞም ኣሉታ ስምዒት ሳብጀኖሚክ ኣር ኤን ኤ(subgenomic RNA) ሞለክዩል ካብ ተዛማዲኦም ኣዎንታ ስምዒት ኤም ኣር ኤን ኤ(mRNAs) ይኽተል።
The replicated positive-sense genomic RNA becomes the genome of the progeny viruses.
እቲ ዝተባዝሐ ኣወንታዊ-ሰንስ ጂኖም ናይ RNA ናብ ጂኦም ናይ ፕሮገኒ ቫይረስ ተቀይሩ።
The mRNAs are gene transcripts of the last third of the virus genome after the initial overlapping reading frame.
ድሕሪ እዚ መበገሲ ምድራስ ኣቃዉማ ንባብ፡እዚ ኤምኣርኤ ናይ መወዳእታ ሳልሳይ ናይዚ ቫይረስ ጂኖም ጽሑፍ ጂን እዩ።
These mRNAs are translated by the host's ribosomes into the structural proteins and a number of accessory proteins.
እዞም mRNAs በቶም ኣኣንገድቲ ራይቦሶም ናብቲ ቅርጻዊ ፕሮቲንን ተወሰኽቲ ፕሮቲንን ፡ ኢዮም ዝቕየሩ፡፡
RNA translation occurs inside the endoplasmic reticulum.
ናይ RNA ምቅይያራት ኣብ ኢንዶፕላስሚክ ረቲኩሉም ይካየድ
The viral structural proteins S, E, and M move along the secretory pathway into the Golgi intermediate compartment.
እቲ ቫይረሳዊ ቅርጺ ናይ ፕሮቲን S ; E; ከምኡ’ውን M፡ ብ ምስጢራዊ መንገዲ ናብቲ ጎልጂ መተሓላለፊ ይሰግሩ።
There, the M proteins direct most protein-protein interactions required for assembly of viruses following its binding to the nucleocapsid.
ኣብዚ- እቲ M ፕሮቲን ነቲ ናይ ፕሮቲን-ፕሮቲን ምትሕብባራት ኣንፈት ይህብ፡ እዚ ድማ፡ ነቲ ናይ ቫይረስ ምጽንባራት ድሕሪ ምስቲ ኒክሎካፕሲድ ምጥባቁ ዝግበር ኢዩ።
Progeny viruses are then released from the host cell by exocytosis through secretory vesicles.
ዉላድ ቫይረሳት ካብ መዕቆቢ ውሃዮ ብ ኤሶሲቶሲስ ብመገዲ ሰክሪታሪ ማይ-ምዕጎ ተዘርጊሑ።
The interaction of the coronavirus spike protein with its complement host cell receptor is central in determining the tissue tropism, infectivity, and species range of the virus.
ምትሕውዋስ ናይ ኮሮና ቫይረስ ምልጋብ ፕሮቲን ምስ ተጻባኢ ዋሃዮ ተቀባሊ፡ ቀንዲ ማኣከላይ ወሳኒ ናይ ኣካሊት ትሮፒዝም፡ ውጽኢት ዘይብሉን ዓሌት ዝርገሐ ቫይረስ እዩ።
The SARS coronavirus, for example, infects human cells by attaching to the angiotensin-converting enzyme 2 (ACE2) receptor.
ንኣብነት እዞም ሳርስ ኮሮናቫይረስ ምስ ACE2 ተቐባሊ ብምትሕሓዝ ንናይ ሰብ ወሃዮ የርክስ።
The scientific name for coronavirus is Orthocoronavirinae or Coronavirinae.
ናይ ኮሮና ቫይረስ ናይ ሳይንስ ስሙ ኦርታኮሮናቪሪነ (Orthocoronavirinae) ወይ ኮሮናቪሪነ (coronavirinae) ኢዩ፡፡
Coronaviruses belong to the family of Coronaviridae, order Nidovirales, and realm Riboviria.
ኮሮናቫይረሳት ካብ ስድራ ኮሮናቢሪዳ (Coronaviridae)፡ መስርዕ ኒዶቪራልስን (Nidovirales) ኣየራት ሪቦቪርያ (Riboviria)።
Genus Betacoronavirus; type species: Murine coronavirus
ጅንስ ቤታ-ኮሮና-ቫይረስ፡ ዓይነት ዓሌት፡ ናይ ኣንጭዋ ኮሮና-ቫይረስ
Species: Betacoronavirus 1 (Bovine Coronavirus, Human coronavirus OC43), Human coronavirus HKU1, Murine coronavirus, Pipistrellus bat coronavirus HKU5, Rousettus bat coronavirus HKU9, Severe acute respiratory syndrome-related coronavirus (SARS-CoV, SARS-CoV-2), Tylonycteris bat coronavirus HKU4, Middle East respiratory syndrome-related coronavirus, Hedgehog coronavirus 1 (EriCoV)
ዘርኢ፡ ቤታ ኮሮና ቫይረስ 1 (ቦቪን ኮሮና ቫይረስ፡ሁማን ኮሮና ቫይረስ OC43) ሁማን ኮሮና ቫይረስ HKU1፡ ሙሪን ኮሮና ቫይረስ፣ ፒፒስትረሉስ መንካዕ ኮሮና ቫይረስ HKU5፡ ርዩሰተስ መንካዕ ኮሮና ቫይረስ HKU9፡ ሓደገኛ ንጡፍ ስርዓተ ምስትንፋስ ጸገም ምስ ኮሮና ቫይረስ ዝተሓሓዝ ((SARS-CoV, SARS-CoV-2)፡ ታይሎንስተሪስ መንካዕ ኮሮና ቫይረስ HKU4፡ ማእከላይ ምብራቕ ምስትንፋስ ጸገም ምስ ኮሮና ቫይረስ ዝተሓሓዝ፡ ሀጅሆግ ኮሮናቫይረስ 1 (EriCoV)
Species: Beluga whale coronavirus SW1, Infectious bronchitis virus
ጅር(ንኣሽቱ ህይወታውን)፡በ ሉጋ ናይ ዓሳ ነባሪ ኮሮናቫይረስ SW1፡ ረክሳዊ ነድሪ ጉርጉማ ቫይርስ
The most recent common ancestor (MRCA) of all coronaviruses is estimated to have existed as recently as 8000 BCE, although some models place the common ancestor as far back as 55 million years or more, implying long term coevolution with bat and avian species.
እቲ ቀንዲ ፍሉጥ መበገሲ ዓሌት መርካ( MRCA) ካብ ኩሉ ኮሮና ቫይረስ ቅድሚ 8000 ልደተ ክርስቶስ ከምዝነበረ ይግመት ዋላ ገሊኦም 55 ሚሊዮን ዓመት ወይ ልዕሊኡ ተበሉ፡ ናይ መንካዕን ካልኦት ኣእዕዋፍ ተዳባሊቁ ነዊሕ ጊዜ ወሲዱ ኢዩ ብምባል።
The most recent common ancestor of the alphacoronavirus line has been placed at about 2400 BCE, the betacoronavirus line at 3300 BCE, the gammacoronavirus line at 2800 BCE, and the deltacoronavirus line at about 3000 BCE.
እቲ ዝቀረበ ፉሉጥ ዝኾነ ዓሌት ናይ ኣልፋ ኮሮና ቫይረስ ዓሌት ቅድሚ 2400 ቅድመ ልደተ ክርስቶስ፡ ናይ ቤታኮሮና ቫይረስ ድማ 3300 ቕድመ ልደተ ክርስቶስ፡ ናይ ጋማ ኮሮና ቫይረስ 2800 ቅድመ ልደተ ክርስቶስ፡ ከምኡ’ውን ናይ ደልታኮሮና ቫይረስ 3000 ልደተ ክርስቶስ ይርከብ
The large number of host bat and avian species, and their global range, has enabled extensive evolution and dissemination of coronaviruses.Many human coronavirus have their origin in bats.
ከም በዓል መንካዕን ዓሌት ኣዕዋፍን ዝርግሖኦም ዝዓበየ ምዕባለን ዝርገን ንኮሮና ቫይረስ ክህልዎ ኣኽኢሉ እዩ። ዝበዝሐ ናይ ደቂ ሰባት ቫይረስ መበገሲኦም መንከዓት ኢየን።
More recently, alpaca coronavirus and human coronavirus 229E diverged sometime before 1960.
ቕድሚ ውሕዱት ግዚያት፡ ኣልፓጃ ቾሮና-ቫይረስ ን ናይ ሰባት ኮሮና-ቫይረስን 229E ፋሕ ኢሎም፡ እዚ ድማ ኣብ ገለ ግዚያት ቅድሚ 1960 ኢዩ
MERS-CoV emerged in humans from bats through the intermediate host of camels.
MERS-CoV ናብ ሰባት ዝተመሓላለፈሎ መንገዲ፡ ካብ መንካዕ ብምብጋስ ኮይኑ ፡ ኣግማል ድማ ኣኣንገድቲ ናይ ምምሕልላፍ ኮይነን ኣገልጊለን።
MERS-CoV, although related to several bat coronavirus species, appears to have diverged from these several centuries ago.
MERS-CoV ምንም እካ ምስ ብዙሕ ናይ መንካዕ ኮሮናቫይረሳ ጅር ይዛመድ፡ግን ካብ ብዙሕ ዘመናት ተፈላልዩ ይነብር ነይሩ።
The most closely related bat coronavirus and SARS-CoV diverged in 1986.
እቲ ኣዝዩ ተመሳሳሊ ናይ መንካዕ ኮሮና-ቫይረስ ን SARS-CoV ን ኣብ 1986 ኣስፋሕፊሑ።
A possible path of evolution, of SARS coronavirus and keen bat coronaviruses, suggests that SARS related coronaviruses coevolved in bats for a long time.
ፈልቂ ናይ ኮሮና ቫይረስ ኣብ መንካዕ ካብ ሳርስ(SARS) ኮሮና ቫይረስን ቀንዲ መንካዕ ኮሮና ቫይረስን ንነዊሕ ንግዜ ዝማዕበለ ክከውን ተክእሎ ኣሎዎ።
In the 1790s, equine coronavirus diverged from the bovine coronavirus after a cross-species jump.
ኣብ 1970`ታት፡ ናይ ፈረስ ኮሮና-ቫይረስ ካብ ናይ ከብቲ ኮሮና-ቫይረስ ፡ ተመሓላሊፉ ወይ ዞሪቁ፡ እዚ ድማ ድሕሪ እቲ ኣብ ዝተፈላለዩ ዓሌት ዘለዎም እንስሳታት ዝላባዕ ሕማም (cross-species) ምክሳቱ ኢዩ።
Later in the 1890s, human coronavirus OC43 diverged from bovine coronavirus after another cross-species spillover event.
ድሕሪ 1890ታት ግዝያት፡ እቲ ናይ ወዲ ሰብ ኮሮና-ቫይረስ OC43 ዝዓይነቱ ፡ ካብቲ ናይ ከብቲ ኮሮና-ቫይረስ ፈሊቁን ዘሪቁን ፡ እዚ ድማ ድሕሪ ናይ ዝተፈላለዩ ዓሌታት ዝመሓላለፍ ናይ ቫይረስ ምዝራቅ ኩነት ምፍጻሙ ኢዩ።
It is speculated that the flu pandemic of 1890 may have been caused by this spillover event, and not by the influenza virus, because of the related timing, neurological symptoms, and unknown causative agent of the pandemic.
ኣብ 1890 ዓለምለኻው ዝርገሐ ሕማም ሰዓል ብ ኢንፍሊወንዛ ቫይረስ ዘይኮነ በዚ ዘሎ ኩነታት ዝሰዓበ ከም ኮነ ይግመት ምኽንያቱ እቲ ግዜን ናይ ኒሮሎጂካል ትርእዮታትን ዘይተፈልጡ ኣስዓብቲ ሕማማትን ሕደ ስለ ዝኮነ
Human coronavirus OC43 besides causing respiratory infections is also suspected of playing a role in neurological diseases.
ናይ ደቂሰባት ኮሮና ቫይረስ OC43 ብጀካ ኣብ ስርዓት ምስትንፋስ ኣብ ናይ መትንታት ሕማም እውን ተራ ከም ዘለዎ ይጥርጠር።
In the 1950s, the human coronavirus OC43 began to diverge into its present genotypes.
ኣብ 1950 ናይ ደቂ ሰብ ኮሮና ቫይረስ OC43 ናብዚ ሕጂ ዘለዎ ዓለት ከም ዝተፈለየ ይሕበር።
Phylogentically, mouse hepatitis virus (Murine coronavirus), which infects the mouse's liver and the central nervous system, is related to human coronavirus OC43 and bovine coronavirus.
ፊሎጀንቲካሊ፡ ናይ ኣንጭዋ ቫይረስ ናይ ወይቦ (Murine coronavirus)፡ ነቲ ናይ ኣንጭዋ ጸላም ከብዲን ናይ ነርቭ ሲስተም ዝጸሉ ኮይኑ ምስ ናይ ወዲ-ሰብ ኮሮና-ቫይረስ OC43 ን ምስ ናይ ከብቲ ኮሮና-ቫይረስን ምትሕሓዝ ኣለዎ።
Human coronavirus HKU1, like the aforementioned viruses, also has its origins in rodents.
ናይ ሰብ ኮሮናቫይረስ HKU11፡ ልክዕ ከም እቲ ኣቀዲሙ ዝተጠቅሰ ቫይረስ ከምኡ’ዉን መበቆል ቀርጣፊ ኣለዎ።
Coronaviruses vary significantly in risk factor.
ኣብ ሓደገኝነቶም ምርኩስ ብምግባር ኮሮና-ቫይረስ ይፈላለዩ ኢዮም።
Some can kill more than 30% of those infected, such as MERS-CoV, and some are relatively harmless, such as the common cold.
ገሊኦም 30 ሚእታዊት ናይ ዝተለኸፉ ሰባት ክቀትሉ ይክእሉ ከም በዓል መርስ ኮቭ( MERS-CoV) ገሊኦም ደሓን ኢዮም ከም በዓል ሰዓል።
Coronaviruses can cause colds with major symptoms, such as fever, and a sore throat from swollen adenoids.
ኮሮና ቫይረስ ጉንፋዕ ምስ ዓበይቲ ምልክታት ከም ረስኒን ቃንዛ ጎረሮን ካብ ምሕባጥ ጎረሮ ከኸትል ይኽእል።
Coronaviruses can cause pneumonia (either direct viral pneumonia or secondary bacterial pneumonia) and bronchitis (either direct viral bronchitis or secondary bacterial bronchitis).
ኮሮና ቫይረስ ኖሞንያ ከስዕብ ይክእል(ብቅትታ ኒሞንያ ሕማም ወይ ድማ ካልኣይ ባክተርያ ሕማም) ከምኡ’ዉን ነድሪ ጉርጉማ (ቅትታዊ ነድሪ ጉርጉማ ወይ ድማ ካልኣይ ባክተርያ ጉርጉማ)።
The human coronavirus discovered in 2003, SARS-CoV, which causes severe acute respiratory syndrome (SARS), has a unique pathogenesis because it causes both upper and lower respiratory tract infections.Six species of human coronaviruses are known, with one species subdivided into two different strains, making seven strains of human coronaviruses altogether.
እቲ ናይ ወዲ-ሰብ ኮሮና ቫይረስ ኣብ 2003 ተረኺቡ፡ እቲ SARS-CoV፡ ነቲ ከቢድ ናይ ምስትንፋስ ስይንድሮም (SARS) ዘስዕብ ፡ ሓደ ፍሉ ሰበብ-ሕማም ኣለዎ፡ ምኽንያቱ ፡ ላዕለዋይን ታሕተዋይን ናይ ምስትንፋስ ረኽሲ ስለ ዘስዕብ ሽዱሽተ ዓሌታት ናይ ወዲ-ሰብ ዝዓይነቶም ኮሮና ቫይረስ ተፈሊጦም ኣለዉ፡ እቲ ሓደ ዓሌት ድማ ኣብ ክልተ ፈትሊ ይፍለ፡ በዚ ድማ ተጠቃሊሎም 7 ዓይነት ናይ ደቂ-ሰብ ዓይነታት ኮሮና-ቫይረስ ይኾኑ ማለት ኢዩ
Four of these coronaviruses continually circulate in the human population and produce the generally mild symptoms of the common cold in adults and children worldwide: -OC43, -HKU1, HCoV-229E, -NL63.
ኣርባዕተ ካብዞም ኮሮና ቫይረስ ኣብ ደቂ ሰባት ኩሉ ግዜ ይመሓላለፉ። ፎኪስ ምልክታት ናይ ሰዓል ኣብ ኡኩላት ሰባትን ህጻናትን የርእዩ። OC43, -HKU1, HCoV-229E, -NL63
Coronaviruses cause about 15% of commons colds.
ኮሮናቫይረስ ከባቢ 15% ናይ ሰዓላት ጠንቂ እዩ።
The majority of colds are caused by rhinoviruses.
እቶም ዝበዝሑ ሰዓላት ብ ሪኖ-ቫይረስ ኢዮም ዝስዕቡ።
The four mild coronaviruses have a seasonal incidence occurring in the winter months in temperate climates.
ኣርባዕተ ብርቱዕ ዘይኮነ ኮሮና ቫይረስ ወቕታዊ ጽልዋ ከም ዘለዎ ኣብ ሓጋይ ኣዋርሓትን ኣብ ሙቀት ኩነታትን ተራእዩ።
There is no preference towards a particular season in tropical climates.
ወልሓደ መግለጺ ብዛዕባ ሓደ ወቕቲ ትሮፒካዊ ክሊማ የለን
Four human coronaviruses produce symptoms that are generally mild:
ኣርባዕተ ናይ ደቂ ሰባት ኮሮና ቫይረስ ሓፈሻዊ ፎኪስ ምልክታት የርእዩ።ስ
The virus was officially named the SARS coronavirus (SARS-CoV).
እዚ ቫይረስ ብወግዒ ኮቪድ (SARS-CoV) ተሰምዩ።
More than 8,000 people were infected, about ten percent of whom died.
ክሳብ 8,000 ሰባት ተለኺፎም፡ ካብኣቶም ድማ እቶም ዓሰርተ ካብ ሚእቲ ሞይቶም።
In September 2012, a new type of coronavirus was identified, initially called Novel Coronavirus 2012, and now officially named Middle East respiratory syndrome coronavirus (MERS-CoV).
ኣብ መስከረም 2012፡ ሓደ ፍሉይ ዓይነት ኮሮና ቫይረስ ተቀልቂሉ፡ ኣብ መጀመርያ ኖቨል ኮሮና ቫይረስ ዝብል ስያመ ተዋሂብዎ ሕጂ ግን ብወግዒ ናይ ማእከላይ ምብራቕ ናይ ምስትንፋስ ስይንድሮመ ኮሮና-ቫይረስ (MERS-CoV) ተባሂሉ ይጽዋዕ ኣሎ።
The World Health Organization issued a global alert soon after.
ውድብ ጥዕና ዓለም ጸኒሑ ኢዩ ዓለማዊ መጠንቀቕታ ሂቡ።
The WHO update on 28 September 2012 said the virus did not seem to pass easily from person to person.
ውድብ ዓለማዊ ጥዕና ብዕለት 28 መስከረም 2012 ከም ዝሓበሮ እቲ ቫይረስ ካብ ሓደ ሰብ ናብ ካልእ ብቐሊሉ ኣይመሓላለፍንዩ።
However, on 12 May 2013, a case of human-to-human transmission in France was confirmed by the French Ministry of Social Affairs and Health.
እንተኮነ፡ ኣብ ግንቦት 12፡ 2013፡ ካብ ሰብ ናብ ሰብ ከም ዝተመሓላለፈ መረጋገጺ ጉዳይ ድማ ብ ናይ ፈረንሳ ሚኒስተር ናይ ማሕበራዊ ጉዳያትን ጥዕናን፡ ከምዝተዋህበ ተፈሊጡ።
In addition, cases of human-to-human transmission were reported by the Ministry of Health in Tunisia.
ከም ተወሳኺ፡ ኣብ ቱኒዝያ ኩነት ምትሕልላፍ ካብ ሰብ ናብ ሰብ ተነጊሩ።
Two confirmed cases involved people who seemed to have caught the disease from their late father, who became ill after a visit to Qatar and Saudi Arabia.
ክልተ ዝተረጋገጸ ኩነት፡ ነዚ ሕማም ካብ ናይ ዳሕረዋይ ኣብኦም ዝተታሕዙ ይመስሉ። እዚ ድሕሪ ናይ ቀጠርን ሱዕዲ ዓረብ መገሸኦምን ሓሚሞም።
Despite this, it appears the virus had trouble spreading from human to human, as most individuals who are infected do not transmit the virus.
ብ ኣንጻር ናይዚ፡ እዚ ቫይረስ ካብ ሰብ ናብ ሰብ ንክመሓላለፍ ጸገማት ጸገማት ከም ዘለዎ ተራእዩ፡ እዚ ድማ እቶም ዝበዝሑ ዝተለኽፉ ነቲ ሕማም ስለ ከም ዘየመሓላልፍዎ ስለ እተፈልጠ ኢዩ
The final name for the virus is Middle East respiratory syndrome coronavirus (MERS-CoV).
እቲ ናይ መወዳእታ ሽማ ናይቲ ቫይረስ ፡ ማእከላይ ምብራቕ ናይ ምስትንፋስ ስይንድሮም ኮሮና-ቫይረስ ተባሂሉ ይጽዋዕ (MERS-CoV)።
The only U.S. cases (both survived) were recorded in May 2014.In May 2015, an outbreak of MERS-CoV occurred in the Republic of Korea, when a man who had traveled to the Middle East, visited four hospitals in the Seoul area to treat his illness.
እቶም ናይ ሕቡራት መንግስትታት ኣሜሪካ ዝተረኽቡ ካልኦት ዝዳሓኑ ኣብ ግንቦት 2014 ተመዝጊቦም ነይሮም።ኣብ ግንቦት 2015 ለበዳ ናይ ኤምኢኣርኤስ-ኮቭ ኣብ ሪፓብሊክ ኮርያ ኣጋጢሙ። እዚ ሓደ ናብ ማእከላይ ምብራቅ ዝገሸ፡ናብ 4 ሕክምናታት ኣብ ኣከባቢ ሰዎል ሕማሙ ምስ ተቖጻጸረ ተረኺቡ።
This caused one of the largest outbreaks of MERS-CoV outside the Middle East.
ኣብ ማእከላይ ምብራቕ ብብዙሕ ዓቀን መርስ (MERS-CoV) ክዝርጋሕ ኣስዒቡ እዩ።
As of December 2019, 2,468 cases of MERS-CoV infection had been confirmed by laboratory tests, 851 of which were fatal, a mortality rate of approximately 34.5%.
ኣብ ታሕሳስ 2019 ፡ 2,468 ኩነት ናይ መርስ-ኮቭ መልከፍቲ ብፈተና ክፍሊ መርመራ ተረጋጊጹ ነይሩ፡፡ 851 ካብኣቶም ብጽኑዕ ዝሓመሙ ክኮኑ ከለዉ፡ መጠን ሞት ከኣ ብገምጋም 34.5% እዩ ።
In December 2019, a pneumonia outbreak was reported in Wuhan, China.
ኣብ ታሕሳስ 2019፡ ናይ ኒሞንያ ንስፍሕፋሕ ኣብ ዉሃን ቻይና ተራእዩ
On 31 December 2019, the outbreak was traced to a novel strain of coronavirus, which was given the interim name 2019-nCoV by the World Health Organization (WHO), later renamed SARS-CoV-2 by the International Committee on Taxonomy of Viruses.
ኣብ ታሕሳስ 31, 2019፡ እቲ ምስፍሕፋሕ ናብቲ ኖቨል ስትረይን ኮሮና-ቫይረስ ተቐዲሑ፡ በዚ ድማ ግዚያዊ ሽም 2019-nCoV ዝብል ብ ውድብ ጥዕና ዓለም (WHO) ተዋሂብዎ፡ ጸኒሑ’ውን ሽሙ ናብ SARS-CoV-2 ዝብል ተቀይሩ፡ ብ ዓለማዊ ኮሚቴ ታክሶኖሚ ናይ ቫይረስ።
Some researchers have suggested the Huanan Seafood Wholesale Market may not be the original source of viral transmission to humans.As of 17 April 2020, there have been at least 153,822 confirmed deaths and more than 2,240,191 confirmed cases in the coronavirus pneumonia pandemic.
ገለ-ገለ ተመራመርቲ ከም ዝብልዎ ሁናን ናይ ባሕሪ መግቢ መሸጣ ሹቅ ምንጪ ናይ ኮሮና ቫይረስ ዘይክኸውን ይኽእል እዩ። ክሳዕ 17 ሚያዝያ 2020፡ 153,822 ዝሞቱ፡ 2,240,191 ድማ ብኮሮና ቫይረስ ዝተለኽፉ ነይሮም።
The Wuhan strain has been identified as a new strain of Betacoronavirus from group 2B with approximately 70% genetic similarity to the SARS-CoV.
እቲ ናይ ዉሃን ስትረይን፡ ከም ሓድሽ ቤታ-ኮሮና ቫይረስ ካብ ጉጅለ 2B ምስ ኣስታት 78% ጀነቲካዊ ምምስሳላት ምስ SARS-CoV፡ ዘለዎ ኮይኑ ተፈሊጡ።
The virus has a 96% similarity to a bat coronavirus, so it is widely suspected to originate from bats as well.
እዚ ቫይረስ ምስ ናይ መንካዕ ኮሮና ቫይረስ 96 ሚእታዊት ተመሳሳልነት ስለ ዘለዎ ምንጩ ካብ መንካዕ ከይከውን ይጥርጠር።
The pandemic has resulted in travel restrictions and nationwide lockdowns in several countries.
እዚ ለበዳ ናይ ጉዕዙ ምጉንዳብን፡ ሃገራዊ ዕጻዋ ኣብ ኣዝየን ብዙሓት ሃገራት ኣኸቲሉ ኢዩ።
Coronaviruses have been recognized as causing pathological conditions in veterinary medicine since the 1930s.
ኮረና ቫይረስ ካብ 1930 ጀሚሩ ከም ስነ-ሕማማዊ ጠንቂ ኣብ ናይ እንስሳታት ሕማም መድሃኒት ምኻኑ ተኣሚኑሉ እዩ።
Except for avian infectious bronchitis, the major related diseases have mainly an intestinal location.
ብጀካ ካብ ኣዕዋፍ ዝመጽእ ሕማም ጉርጉማ እቶም ዝበዝሑ ሕማማት ዝበዝሐ ካብ ዉሽጢ መዓናጡ ኢዮም ዝመጹ።
Coronaviruses primarily infect the upper respiratory and gastrointestinal tract of mammals and birds.
ኮሮና ቫይረስ ብመጀመርታ ነቲ ላዕለዋይ ክፋል ናይ ምስትንፋስን ፡ ነቲ ከስዐ-መዓንጣ ናይ መጥበውቲን ኣዝዩ ከም ዝሃሲ ተፈሊጡ።
They also cause a range of diseases in farm animals and domesticated pets, some of which can be serious and are a threat to the farming industry.
ኣብ ናይ ሕርሻ እንስሳታትን፡ እንስሳ ዘቤትን ውን ዝተፈላለዩ ሕማማት የስዕቡ ኢዩም፡ ብፍላይ ኣብ ገሊኡ ኣዝዩ ከቢድ ጉድኣት ነቲ ናይ ሕርሻ ኩባንያ ከስዕብ ይኽእል።
In chickens, the infectious bronchitis virus (IBV), a coronavirus, targets not only the respiratory tract but also the urogenital tract.
ኣብ ደርሁት ረኽሲ ናይ ሳንቡእ ቫይረስ (IBV)፡ ኮሮና ቫይረስ ናይ ስርዓት ምስትንፋስ ዘይኮነ እንኮላይ ንስርዓት መፍረ’ውን የጥቅዕ።
The virus can spread to different organs throughout the chicken.
እዚ ቫይረስ ናብ ዝተፈላለዩ ህዋሳት ኣብ ደርሖ ከስፋሕፍሕ ይኽእል ኢዩ
Economically significant coronaviruses of farm animals include porcine coronavirus (transmissible gastroenteritis coronavirus, TGE) and bovine coronavirus, which both result in diarrhea in young animals.
ቁጠባዊ ጽልዋ ኮረና ቫይረስ ኣብ ናይ ሕርሻ እንስሳታት ከም ፖርሲን ኮረና ቫይረስ(ተምሓላለፊ ጋስትሮንተሪስ ኮረና ቫይረስ(transmissible gastroenteritis coronavirus, TGE))ን ቦቪን ኮረና ቫይረስን(bovine) እዮም።ክልቲኦም’ውን ውጽኣት የስዕቡሎም ንነኣሽቱ እንስሳታት።
Feline coronavirus: two forms, feline enteric coronavirus is a pathogen of minor clinical significance, but spontaneous mutation of this virus can result in feline infectious peritonitis (FIP), a disease associated with high mortality.
ናይ ድሙ ኮሮና ቫይረስ፡ ክልተ ቅርጺታት፡ ናይ ድሙ አንተሪክ ኮሮና-ቫይረስ፡ ሰበብ-ሕማም ናይ ሓደ ን ኢእተይ ክሊኒካል ኣገዳስነት ዘለዎ ኢዩ፡ እንተኾነ እቲ ቀጻሊ ለውጢ ናይ ኮሮና-ቫይረስ ነቲ ናይ ድሙ ተላኻፊ ፐርቲኖቲስ (FIP) ከስእዕብ ይኽእል፡ እዚ ሕማም ምስ ዓቢ ሞራላዊ ምትሕሓዝ ኣለዎ።
Similarly, there are two types of coronavirus that infect ferrets: Ferret enteric coronavirus causes a gastrointestinal syndrome known as epizootic catarrhal enteritis (ECE), and a more lethal systemic version of the virus (like FIP in cats) known as ferret systemic coronavirus (FSC).
ብ ተመሳኣስሊ፡ ክልተ ዓይነት ኮሮና-ቫይረ ኣሎ ነቲ ፈሪቲስ ዘጥቅዕ፡ ፈሪ ኢንትሪክ ኮሮና-ቫይረስ ጠንቂ ናይ ፡ጋስትሮኢንተስቲናል ስይንድሮም ኣፒዞቲክ ክታራል አንተረቲስ (ECE) ኢዩ፡ ከምኡ’ውን ተወሳኺ ሲስተማቲካዊ ክፋል ናይቲ ቫይረስ (ከም FIP ኣብ ደማሙ) ኮይኑ፡ ፈረተስ ሲስተማዊ ኮሮና-ቫይረስ (FSC) ድማ ይበሃል
There are two types of canine coronavirus (CCoV), one that causes mild gastrointestinal disease and one that has been found to cause respiratory disease.
ክልተ ዓይነት ናይ ከልቢ ኮሮና ቫይረስ (CCoV) ኣሎ ፡ እቲ ቀዳማይ ፈኪስ ናይ ከስዐ-መዓንጣዊ ሕማም ዘስዕብ ኮይኑ እቲ ካል ኣይ ድማ ናይ ምስትንፋስ ሽግራት ስለዘስዕብ ሙኻኑ ኢዩ
Mouse hepatitis virus (MHV) is a coronavirus that causes an epidemic murine illness with high mortality, especially among colonies of laboratory mice.
ናይ ኣንጭዋ ሀፓቲቱስ ቫይረስ (MHV)- ኮሮና ቫይረስ ኮይኑ ለበዳ ናይ ሙሪን ሕማም የኸትል ብ ልዑል ናይ ሞት ሓደጋ፡ ብፍላይ ኣብ መንጎ ናይ ላባራቶሪ ኣናጹ።
Sialodacryoadenitis virus (SDAV) is highly infectious coronavirus of laboratory rats, which can be transmitted between individuals by direct contact and indirectly by aerosol.
ስያሎዳክርዮደኒቲስ (Sialodacryoadenitis) ቫይረስ( SDAV) ዝላዓለ ተለካፊ ኮሮናቫይረስ ናይ ክፍሊ መርመራ ኣናጹ እዩ። ኣብ መንጎ ውልቃውያን ብቀጥታን ዘይቀጥታዊ ክመሓላለፍ ይኽእል።
Some strains of MHV cause a progressive demyelinating encephalitis in mice which has been used as a murine model for multiple sclerosis.
ገለ ጨደድቲ ናይ MHV ቀጻሊ ዕቤት ደምይሊናቲንግ ኢንሰፋሊቲስ ኣብ ኣናጹ የስዕብ።ከም ኣንጭዋ መሰል ናይ ብዙሕ ሉምሉም ተጠቂሙ።
Significant research efforts have been focused on elucidating the viral pathogenesis of these animal coronaviruses, especially by virologists interested in veterinary and zoonotic diseases.
ኣብ ምንጻር ኣመጻጽኣ ሕማም ቫይራል ናይ እንስሳ ኮሮናቫይረስ፡ ብፍላይ ብ ስነ-ቫይረሰኛ ዝግደስ ኣብ ሓኪም እንስሳን ሕማማት ዞኖቲክ ኣገዳሲ ጸዓታት መጽናዕቲ ጸቂጥሉ።
Porcine coronavirus (transmissible gastroenteritis coronavirus of pigs, TGEV).
ናይ ሓሰማ ኮሮና-ቫይረስ (ተመሓላላፊ ጋስትሮነትሪቲስ ኮሮና-ቫይረስ ናይ ሓሰማታት፡ TGEV)
Bovine coronavirus (BCV), responsible for severe profuse enteritis in of young calves.
ቦቪን ኮሮና ቫይረስ (BCV) ኣብ ነኣሽቱ ውላዳት ከብቲ(ምራካት) ኣዝዩ ቡዙሕ ጉድኣት ነድሪ መዓናጡ ዘምጽእ እዩ።
Feline coronavirus (FCoV) causes mild enteritis in cats as well as severe Feline infectious peritonitis (other variants of the same virus).
ናይ ዱሙ ኮሮናቫይረስ( FCoV) ፈኩስ ነድሪ መዓናጡ ኣብ ደማሙ፡ማዕረ ማዕሪኡ ከቢድ ነድሪ ቃንጡጥ(መለሳ ካልኦት ናይ ሓደ ዓይነት ቫይረስ) የስዕብ።
the two types of canine coronavirus (CCoV) (one causing enteritis, the other found in respiratory diseases).
እቶም ክልተ ዓይነት ናይ ከልቢ ኮሮና ቫይረሳት (CCoV) (ሓደ ነድሪ ማዓናጡ ካልእ ከኣ ናይ ምስትንፋስ ሕማም የምጽእ)።
Turkey coronavirus (TCV) causes enteritis in turkeys.
ናይ ቱርኪ ኮሮናቫይረስ (TCV) ኣብ ቱርካውያን ረኽሲ ማዓናጡ የምጽእ።
Ferret enteric coronavirus causes epizootic catarrhal enteritis in ferrets.
ፈረት ኢንተሪች ቾሮና-ቫይረስ ን አፒዞቲክ ቻታርሃል ኢንተሪቲስ ኣብ ፈሪቲስ፡ የማዕብል።
Ferret systemic coronavirus causes FIP-like systemic syndrome in ferrets.
ፈረት ሲስተሚክ ኮሮና-ቫይረስ ጠንቂ ናይ FIP-like ሲስተማቲክ ስይንድሮም ኣብ ፈረት ኢዩ።
Rabbit enteric coronavirus causes acute gastrointestinal disease and diarrhea in young European rabbits.
ኮረና ቫይረስ ናይ መዓናጡ ማንቲለ ብርቱዕ ዝኾነ ናይ መዓናጡ ሕማምን ውጽኣትን የስዕበሎም ንናሽቱ ኤውሮፓውያን ማንቲለ።
Porcine epidemic diarrhea virus (PED or PEDV), has emerged around the world.
ሓሰማዊ ኣዕናዊ ናይ ዉጽኣት PED ወይ PEDV)፡ ኣብ ዓለም ተቐልቂሉ ኣሎ።
b'Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
ሕማም ኮሮና ቫይረስ(ኮቪድ-19) ብብርቱዕን ቅጽበታውን እስትንፋሳዊ ምልከት ሕማም ኮሮና ቫይረስ 2 ወይ SARS-CoV-2 ተባሂሉ ብዝጽዋዕ ቫይረስ ዝስዕብ ተላባዒ ወይ ተመሓላላፊ ሕማም ኢዩ።
Common symptoms include fever, cough, and shortness of breath.
ልሙዳት ምልክታት ረስኒ፡ ሰዓል ከምኡውን ሕጽረት ምስትንፋስ የጠቃልሉ።
Other symptoms may include fatigue, muscle pain, diarrhea, sore throat, loss of smell, and abdominal pain.
ካለኦት ምልክታት እዞም ዝስዕቡ የጠቓልል፡ ብርቱዕ ድኻም፡ቅርጥማት ፡ውጽኣት፡ መቑሰልቲ ናይ ጎሮሮ፡ ሽታ ዘይምልላይ፡ ቕርጸት።
The time from exposure to onset of symptoms is typically around five days but may range from two to fourteen days.
እቲ ካብታ ቫይረስ ናብ ነብስኻ ዝኣቱ ናብቲ ምክታት ዝጂምረልካ ዝወስደልካ መ ዓልታት ክሳብ ሓሙሽተ መዓልታት ሙኻኑ ይግምገም፡ እንተኾነ ካብ ክልተ ክሳብ ዓሰርተ-ኣርባዕተ መዓልታት ከኸውን ይኽእል።
While the majority of cases result in mild symptoms, some progress to viral pneumonia and multi-organ failure.
ዝበዝሕ ውጽኢት ድኹም ምልክታት ኣብ ዝኮነሉ ፡ዉሑድ ዕቤት ቫይራል ኒሞንያን ብዙሓት ህዋሳትን የዳኽምን።
As of 17 April 2020, more than 2.24 million cases have been reported across 210 countries and territories, resulting in more than 153,000 deaths.
ክሳብ 17 ሚያዝያ 2020፡ ልዕሊ 2.24 ሚልዮን ግዳያት ናይ 210 ሃገራትን ግዝኣታትን ጸብጻብ ተጌሩ ካብዚ ድማ ልዕሊ 153,000 መጠነ ሞት ተራእዩ።
More than 568,000 people have recovered.The virus is primarily spread between people during close contact, often via small droplets produced by coughing, sneezing, or talking.
ልዕሊ 568,000 ሰባት ጥዕናኦም ናብ ንቡር ተመሊሱ። እዚ ቫይረስ ብ ብቀዳምነት ኣብ መንጎ ሰባት ዝስፍሕፋሓሉ ርሕቀት ኣብ ዘይብሉ ሞት እክብካብ ብዓል ምስዓል፡ ምሕንጣስ፡ ምዝርራብን ዝፍጠሩ ኣዝዮም ደቀቅቲ ማይ መሰል ነጠብጣብ መገዲ ኣቢሉ።
While these droplets are produced when breathing out, they usually fall to the ground or onto surfaces rather than being infectious over long distances.
እዚ ንጣባት ክሳዕ ዝፈረየ፡ትንፋስ ኣብ ዝወጻሉ ኩሉ ግዜ፡ ተለኺፉ ከሎ ነዊሕ መገዲ ከይከደ ኣብ ምድሪ ወይ ኣብ ልዕሊ ምድሪ ይወድቕ።
People may also become infected by touching a contaminated surface and then touching their eyes, nose, or mouth.
ሰባት ምናልባት ነቲ ዝተበከለ ኣከባቢ ብምሓዝ ጸኒሖም ኣፎም፡ ኣፍንጫኦም ወይ ኣዒንቶም ብምሓዝ ክብከሉ ይኽእሉ ኢዮም።
The virus can survive on surfaces up to 72 hours.
እዚ ቫይረስ ኣብ ባይታ ክሳብ 72 ሰዓታት ክጸንሕ ይኽእል።
It is most contagious during the first three days after the onset of symptoms, although spread may be possible before symptoms appear and in later stages of the disease.The standard method of diagnosis is by real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab.
ካብቲ ምልክታት ክ ኣይ ዝጂምር ክሳብ ሰለስተ ማዓልታት ኣብ ዘሎ ግዜ ንምምሕልላፍ እቲ ኣዝዩ ዝመቸአ ግዜ ኢዩ፡ ወላካ እቲ ምምሕልላፍ ምልክታት ከይጀመረ ክትግበር እንተኸኣለ። እቲ ደረጃ ኡ ዝሓለወ ናይ ሕክምና ኣገባብ እዚ real-time reverse transcription polymerase chain reaction (rRT-PCR) ካብ ናይ ጎሮሮ ቅምሶ ብምውሳድ ዝግበር ኢዩ።
The use of masks is recommended for those who suspect they have the virus and their caregivers.
ነቶም በዚ ቫይረስ ዝተለኽፉን ነቶም ተኸናኸንቶምን ፡ ማስክ ክጥቀሙ ኣገዳሲ ኢዩ።
Recommendations for mask use by the general public vary, with some authorities recommending against their use, some recommending their use, and others requiring their use.
ኣብ ኣጠቓቕማ ኣፍ መሸፈኒ ዘሎ ኣተሓሳስባ ካብ ሰብ ናብ ሰብ ይፈላለ እዩ፡ ገለ በዓል መዚ ኣንጻር ዘይምጥቃም፡ገለ ምጥቃም፡ገለ`ውን ጥቕሙ ይሓቱ።
Currently, there is no vaccine or specific antiviral treatment for COVID-19.
ክሳብ ሕጂ ፍሉጥ ጸረ ቫይራል ክንክን ወይ ክታበት ናይ ኮቪድ-19 ኣይተረኽበን።
Local transmission of the disease has been recorded in most countries across all six WHO regions.
ውሽጣዊ ምምሕልላፍ ሕማም ኣብ ዝበዝሓ ሃገራትን ሽዱሽተ ዓለምለኻዊ ውድብ ጥዕና ዓለም (WHO) ዞባታትን ብምውሳኽ ተመዝጊቡ።
Those infected with the virus may be asymptomatic or develop flu-like symptoms such as fever, cough, fatigue, and shortness of breath.
እዞም በዚ ቫይረስ ዝተለኽፉ ሰባት ኣሲምፕቶቲክ (ምልክት ናይ ሕማም ዘይብሎም ግዳያት ኣመሓላለፍቲ ሕማም) ወይ ድማ ሰዓል ዝመስል ምልክታት ከም ረስኒ፡ ምስዓል፡ ድኻም፡ ከምኡውን ሕጽረት ምስትንፋስ ዝኣመሰሉ ምልክታት ከርእዩ ይኽእሉ ኢዮም።
Emergency symptoms include difficulty breathing, persistent chest pain or pressure, confusion, difficulty waking, and bluish face or lips; immediate medical attention is advised if these symptoms are present.
ህጹጽ ምልክታት ከም በዓል ብርቱዕ ሕጽረት ምስትንፋስ፡ብርቱዕ ቃንዛ ኣፍልቢ፡ወይ ጸቕጢ፡ዕግርግር፡ናይ ምንቅስቓስ ጸገም፡ምጽምላው ገጽን ከንፈርን፡እዞም ምልክታት እዚኦም እንተተራእዮም ብቕልጥፍ ሕክምናዊ ኣቓልቦ ክግበረሎም ኣለዎ።
Less commonly, upper respiratory symptoms such as sneezing, runny nose or sore throat may be seen.
ኣብ ሓጺር ግዜ ናይ ላዕለዋይ ስርዓት ምስትንፋስ ምልክታት፡ ምዕንጣስ፡ ጸረርታ ኣፍንጫ፡ ድርቀት ጎሮሮ ክረአ ይከኣል።
Gastrointestinal symptoms such as nausea, vomiting and diarrhoea have been observed in varying percentages.
ናይ ከብዲ/ስቶማኮ ምልክታት ከም ዕግርግር ምባል፡ ተምላስ፡ ውጽኣት፡ ብብዙሕ ሚእታዊት ተራእዩ ኢዩ።
Some cases in China initially presented only with chest tightness and palpitations.
ገለ ግዳያት ኣብ ቻይና ካብ መጀመርያ ናይ ኣፍልቢ ቃንዛን ጸቕጢን ዝነበሮም ኔሮም።
In some, the disease may progress to pneumonia, multi-organ failure, and death.
ኣብ ገለ፡ እቲ ሕማም ናብ ኒሞንያ ክሰጋገር ይኽእል ኢዩ፡ በዚ ድማ ብዙሓት ህዋሳት ካብ ስራሕ ወጻኢ ክኾኑን ሞት ውን ከስዕብ ይኽእል ኢዩ።
This is called the incubation period.
እዚ ድማ ናይ ምጭጫሕ ጊዜ ይባሃል።
The incubation period for COVID-19 is typically five to six days but may range from two to 14 days.
ከም ልሙድ ኮቪድ-19 ዝዓኮሉ ግዜ ካብ 5 ክሳብ 6 ማዓልታት ወይ ውን ካብ 2 ክሳብ 14 ማዓልታት ክወስድ ይኽእል እዩ።
97.5% of people who develop symptoms will do so within 11.5 days of infection.Reports indicate that not all who are infected develop symptoms.
መብርሂታት ከም ዘመልክቶ ኩሎም እቶም ዝተለኽፉ ምልክታት ምዕባለ የርእዩ ማለት ኣይኮነን፡ 97.5% ምልክታት ምዕባለ ዘለዎም ሰባት ኣብ ውሽጢ 11.5 ማዓልታት መልከፍቲ ይረአ።
The role of these asymptomatic carriers in transmission is not yet fully known; however, preliminary evidence suggests that they may contribute to the spread of the disease.
እቲ ግደ ናይዞም ኣሲምፕቶቲክ (ምልክት ናይ ሕማም ዘይብሎም ግዳያት ኣመሓላለፍቲ ሕማም) ኣማሓላለፍቲ ኣብ ግዜ ምምሕልላፍ ክሳብ ሕጂ ምሉእ ብ ምሉእ ኣይተፈልጠን፡ እንተኾነ ቀዳማይ መረጋገጺ ከም ዝሕብሮ ኣብቲ ምምሕልላፍ ኢድ ክህልዎም ከም ዝኽእል ኢዩ፡
The proportion of infected people who do not display symptoms is currently unknown and being studied, with the Korea Centers for Disease Control and Prevention (KCDC) reporting that 20% of all confirmed cases remained asymptomatic during their hospital stay.
መጠን ዝተለኽፉ ሰባት ግን ከኣ ምልክታት ናይዚ ሕማም ዘየርእዩ ክሳብ ሕጂ ዘይተፈልጠን ኣብ መጽናዕቲ ዘሎን ኮይኑ፡ ኣብ ኮርያ ዝመደበሩ ማእከል ምክልኻል ሕማማት (KCDC) 20 ሚእታዊት ናይ በዚ ሕማም ዝተለኽፉ ሰባት አብ ሆስፒታል አብ ዝነበርዎ ግዜ ዝኾነ ምልክታት ናይዚ ሕማም ከምዘየርኣዩ ገሊጹ።
China's National Health Commission began including asymptomatic cases in its daily cases on 1 April; of the 166 infections on that day, 130 (78%) were asymptomatic at the time of testing.
ቻይና ዓለምለኻዊ መዚ ጥዕና፡ ምልክት ሕማም ዘለዎ ማዓልታዊ ጉዳይ ዘማእከለ ኣብ ሚያዝያ 1 ጀሚሩ። 166 ልኹፋት ኣብዛ ማዓልቲ እዚኣ፡ 130 ( 78%) ኣብ ግዜ መርመራ ምልክት ሕማም ኔርዎም።
Both sputum and saliva can carry large viral loads.
ዓኽታን ጥፍጣፍን ሰፊሕ ናይ ቫይረስ ዝርግሐ ከመሓላልፉ ይኽእሉ።
Loud talking releases more droplets than normal talking.
ሃተውቶው ምባል ካብ ልሙድ ኣዘራርባ ዝበሐ ነጠብታ ይፍኑ።።
A study in Singapore found that an uncovered cough can lead to droplets travelling up to 4.5 meters (15 feet).
ኣፍካ ከይሸፈንካ ምስዓል ክሳብ 4.5 ሜትሮ ወይ 15 ጫማ ክጉዓዝ ዝኽእል ነጠብጣብ ከምዘስዕብ ኣብ ሲንጋፖር ዝተገብረ መጽናዕቲ የረጋግጽ።
Though the virus is not generally airborne, the National Academy of Science has suggested that bioaerosol transmission may be possible and air collectors positioned in the hallway outside of people's rooms yielded samples positive for viral RNA.
ሽሕ'ኳ እቲ ቫይረስ ኣብ ኣየር ዘንሳፍፍ እንተዘይኮነ ዓለምለኻዊ ኮለጅ ስነ-ፍልጠት ብያሮዛል ምትሕልላፍ ከምዝከኣልን መብርሂ ሂቦም።ኣከብቲ ኣየር ካብ ቤት ወጻኢ ኣብ ኮሮድዮታት ኮይኖም ናይ ቫይራል RNA ኣወንታዊ ምስክርነት ሂቦም።
Some medical procedures such as intubation and cardiopulmonary resuscitation (CPR) may cause respiratory secretions to be aerosolised and thus result in airborne spread.
ገለ ገለ ናይ ሕክምና መምርሒታት፡ ከም intubation (ናይ ምስትንፋስ ጸገም ንዘለዎም ሰብ ዝሰርሖ ትቦ ናይ ኣካላቶም ናይ ምእታው መስርሕ) ከምኡ`ውን ካርድዮ-ፓልሞናሪ ረሱሲሽን (cardiopulmonary resuscitation (CPR))፡ ናይ ምስትንፋስ ሽግራት ከስዕብን ኣብ ምምሕልላፍ ናይ ብ ኣየር ዝመሓላለፉ ሕማማት ኣወንታዊ ሓገዝ ክግብርን ይኽእል ኢዩ።
While there are concerns it may spread via feces, this risk is believed to be low.The virus is most contagious when people are symptomatic; while spread may be possible before symptoms emerge, the risk is low.
ወላካ ብ ቀልቀል ክመሓላለፍ ከም ዝኽእል ስክፍታ እንተሎ፡ እቲ ሓደጋ ኣዝዩ ውሑድ ኢዩ። እቶም ሰባት ሲምፕቶቲክ (ምልክታት ከለዎም ሕማም ዘመሓላልፉ) ኣብ ዝኾኑሉ እቲ ቫይረስ ተጋዳኢ/ተመሓላላፊ ኣይኮነን፡ እንተኾነ ወላ`ውን ቅድሚ ምልክታት ምጅማር እቲ ምትሕልላፍ ተኽእሎታት ኣለዎ።
The European Centre for Disease Prevention and Control (ECDC) says while it is not entirely clear how easily the disease spreads, one person generally infects two to three others.The virus survives for hours to days on surfaces.
ማእከል ምቁጽጻርን ምክልኻልን ሕማማት ኤውሮጳ ኢሲዲሲ ((ECDC)) ከምዝበሎ፡ ምስፍሕፋሕ እዚ ሕማም ሙሉእ ብሙሉእ ብምንታይ ከምዝመሓላለፍ እንተዘይ ተፈሊጡ፡ሓደ ሰብ ብሓፈሻ ክልተ ወይ ሰለስተ ክልክም ይኽእል። እዚ ቫይረስ ካብ ሰዓታት ክሳብ ማዓልትታት ኣብ መሬት ክገብር ይኽእል።